These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 21968130)

  • 81. Management of antibody-mediated rejection in transplantation.
    Sadaka B; Alloway RR; Woodle ES
    Surg Clin North Am; 2013 Dec; 93(6):1451-66. PubMed ID: 24206861
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients.
    Alachkar N; Lonze BE; Zachary AA; Holechek MJ; Schillinger K; Cameron AM; Desai NM; Dagher NN; Segev DL; Montgomery RA; Singer AL
    Transplantation; 2012 Jul; 94(2):165-71. PubMed ID: 22735712
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients.
    Marfo K; Ling M; Bao Y; Calder B; Ye B; Hayde N; Greenstein S; Chapochnick-Friedman J; Glicklich D; de Boccardo G; Kinkhabwala M; Akalin E
    Transplantation; 2012 Aug; 94(4):345-51. PubMed ID: 22820699
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation.
    Ballew CC; Bergin JD
    Am J Crit Care; 2005 Jan; 14(1):46-51. PubMed ID: 15608108
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo.
    Diwan TS; Raghavaiah S; Burns JM; Kremers WK; Gloor JM; Stegall MD
    Transplantation; 2011 Mar; 91(5):536-41. PubMed ID: 21283064
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
    Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Alloantibodies and the outcome of cadaver kidney allografts.
    Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
    Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of plasmapheresis for acute humoral rejection after heart transplantation.
    Wang SS; Chou NK; Ko WJ; Chi NH; Hung SC; Hsu RB; Yu HY; Chen YS; Chu SH; Tsao CI; Shun CT
    Transplant Proc; 2006 Dec; 38(10):3692-4. PubMed ID: 17175369
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

  • 95. Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
    Zhu L; Lin Z; Xiang Y; Liu S; Chen G
    Clin Transpl; 2009; ():359-60. PubMed ID: 20524298
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: even after one year post-treatment.
    Sberro-Soussan R; Zuberl J; Suberbielle-Boissel C; Legendre C
    Clin Transpl; 2010; ():409-14. PubMed ID: 21696059
    [TBL] [Abstract][Full Text] [Related]  

  • 99. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
    Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA
    Clin Transpl; 2009; ():377-84. PubMed ID: 20524301
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
    Fehr T; Gaspert A
    Transpl Int; 2012 Jun; 25(6):623-32. PubMed ID: 22394269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.